Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;43(3):143-179.

Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections

Samantha Rosenthal, Arnold G Decano, Aiman Bandali, Denise Lai, Gregory E Malat, Tiffany E Bias

Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections

Samantha Rosenthal et al. P T. 2018 Mar.

Abstract

Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors report no commercial or financial interests in regard to this article.

Figures

Figure 1
Figure 1
Chemical Structure of Oritavancin
See this image and copyright information in PMC

References

    1. Food and Drug Administration. FDA approves Orbactiv to treat skin infections. Aug 6, 2014. [Accessed March 1, 2017]. Available at: https://tinyurl.com/ycttnnxj.
    1. Orbactiv (oritavancin) prescribing information. Parsippany, New Jersey: The Medicines Company; 2014.
    1. Belley A, Neesham-Greenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antmicrob Agents Chemother. 2009;53(3):918–925. - PMC - PubMed
    1. Bhavnani SM, Owen JS, Loutit JS, et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004;50:95–102. - PubMed
    1. Yao RC, Crandall LW. Glycopeptides: classification, occurrence, and discovery. In: Nagarajan R, editor. Glycopeptide Antibiotics. New York, New York: Marcel Dekker; 1994. pp. 1–27.

LinkOut - more resources